Design and development of a macrocyclic series targeting phosphoinositide 3-kinase δ

Spencer, Jonathan A. and Baldwin, Ian R. and Barton, Nick and Chung, Chun-Wa and Convery, Máire A. and Edwards, Christopher D. and Jamieson, Craig and Mallett, David N. and Rowedder, James E. and Rowland, Paul and Thomas, Daniel A. and Hardy, Charlotte J. (2020) Design and development of a macrocyclic series targeting phosphoinositide 3-kinase δ. ACS Medicinal Chemistry Letters, 11 (7). pp. 1386-1391. ISSN 1948-5875

[img] Text (Spencer-etal-MCL-2020-Design-and-development-of-a-macrocyclic-series-targeting)
Spencer_etal_MCL_2020_Design_and_development_of_a_macrocyclic_series_targeting.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 3 June 2021.

Download (1MB) | Request a copy from the Strathclyde author

    Abstract

    A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase δ inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties.